nCoV: Rapid Clinical Development of ChAdOx1 nCoV-19
Lead Research Organisation:
University of Oxford
Department Name: UNLISTED
Abstract
ChAdOx1 is a safe and effective vaccine vector that can be used to produce vaccines
against many different diseases. Unlike other rapid vaccine technologies, only a single
dose of the vaccine is likely to be needed. DNA, mRNA and recombinant protein vaccines
typically require two or three doses to achieve protective immunity. ChAdOx1 has been
used to make a Middle East Respiratory Syndrome Coronavirus vaccine which is
protective in non-human primates after a single dose, and is safe and highly immunogenic
in humans as demonstrated in a phase I clinical trial. The same vaccine design has been
followed to produce ChAdOx1 nCoV. We now propose to manufacture this vaccine to
cGMP and conduct a clinical trial in healthy volunteers in the UK. We will work closely with
the MHRA to complete all required testing of the vaccine and obtain regulatory approval in
as short a time as possible, with the aim of initiaiting the clinical trial in June.
We will also work with partners to demonstrate protective efficacy of ChAdOx1 nCoV in
two different animal models. This will provide the necessary information to support further
clinical trials of this vaccine to demonstrate efficacy in humans.
against many different diseases. Unlike other rapid vaccine technologies, only a single
dose of the vaccine is likely to be needed. DNA, mRNA and recombinant protein vaccines
typically require two or three doses to achieve protective immunity. ChAdOx1 has been
used to make a Middle East Respiratory Syndrome Coronavirus vaccine which is
protective in non-human primates after a single dose, and is safe and highly immunogenic
in humans as demonstrated in a phase I clinical trial. The same vaccine design has been
followed to produce ChAdOx1 nCoV. We now propose to manufacture this vaccine to
cGMP and conduct a clinical trial in healthy volunteers in the UK. We will work closely with
the MHRA to complete all required testing of the vaccine and obtain regulatory approval in
as short a time as possible, with the aim of initiaiting the clinical trial in June.
We will also work with partners to demonstrate protective efficacy of ChAdOx1 nCoV in
two different animal models. This will provide the necessary information to support further
clinical trials of this vaccine to demonstrate efficacy in humans.
Technical Summary
This COVID-19 Rapid Response award is jointly funded (50:50) between the Medical Research Council and the National Institute for Health Research. The figure displayed is the total award amount of the two funders combined, with each partner contributing equally towards the project.
ChAdOx1 is a replication-deficient simian adenoviral vector that provides a platform
technology for the production of vaccines against many infectious diseases. For Middle
East Respiratory Syndrome (MERS) coronavirus, a single dose of the ChAdOx1-vectored
MERS vaccine resulted in protection against MERS challenge in non-human primates and
the induction of strong humoral and T cell responses in a Phase I clinical trial. The same
vaccine design has now been followed to produce ChAdOx1 nCoV. Preclinical studies of
the vaccine will be initiated by the end of February. This will include demonstration of
vaccine immunogenicity (antibody and T cell) in mice, followed by vaccine immunogenicity
and efficacy against nCoV-19 challenge in ferrets and non-human primates with
collaborators at PHE Porton Down and NIH. A pre-GMP vaccine seed stock is in
production at Oxford’s GMP manufacturing facility, and will be provided to Advent, Italy,
which will produce the first 1000 doses for clinical studies.
In parallel with preclinical studies and vaccine manufacturing, Oxford will work with the
MHRA on a rapid release testing package. This will employ deep sequencing of the Cell
Harvest and Drug Substance to identify any potential replication competent adenovirus
and adventitious agents rather than following the existing set of in vivo and in vitro assays,
greatly reducing the time to cGMP certification. A phase I/II clinical trial will then be
undertaken to demonstrate vaccine safety and immunogenicity in adults, older adults and
children.
ChAdOx1 is a replication-deficient simian adenoviral vector that provides a platform
technology for the production of vaccines against many infectious diseases. For Middle
East Respiratory Syndrome (MERS) coronavirus, a single dose of the ChAdOx1-vectored
MERS vaccine resulted in protection against MERS challenge in non-human primates and
the induction of strong humoral and T cell responses in a Phase I clinical trial. The same
vaccine design has now been followed to produce ChAdOx1 nCoV. Preclinical studies of
the vaccine will be initiated by the end of February. This will include demonstration of
vaccine immunogenicity (antibody and T cell) in mice, followed by vaccine immunogenicity
and efficacy against nCoV-19 challenge in ferrets and non-human primates with
collaborators at PHE Porton Down and NIH. A pre-GMP vaccine seed stock is in
production at Oxford’s GMP manufacturing facility, and will be provided to Advent, Italy,
which will produce the first 1000 doses for clinical studies.
In parallel with preclinical studies and vaccine manufacturing, Oxford will work with the
MHRA on a rapid release testing package. This will employ deep sequencing of the Cell
Harvest and Drug Substance to identify any potential replication competent adenovirus
and adventitious agents rather than following the existing set of in vivo and in vitro assays,
greatly reducing the time to cGMP certification. A phase I/II clinical trial will then be
undertaken to demonstrate vaccine safety and immunogenicity in adults, older adults and
children.
People |
ORCID iD |
Sarah Gilbert (Principal Investigator) |
Publications
Barrett JR
(2021)
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
in Nature medicine
Barrett JR
(2021)
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
in Nature medicine
Bewley KR
(2021)
Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques.
in Science advances
Clemens SAC
(2021)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
in Nature communications
Dejnirattisai W
(2021)
Antibody evasion by the P.1 strain of SARS-CoV-2.
in Cell
Emary KRW
(2021)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
in Lancet (London, England)
Feng S
(2021)
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
in Nature medicine
Flaxman A
(2021)
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
in Lancet (London, England)
Description | Meeting with Andrew Mitchell MP Minister for Development and Africa and FCDO staff |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
URL | https://www.devex.com/news/minister-promises-to-act-as-experts-raise-alarm-over-uk-pandemic-readines... |
Description | Member of Joint Committee on Vaccination and Immunisation |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | The JCVI advises the UK government on vaccine strategy and roll out. |
Description | COV19 OxfordVacc-01 |
Amount | £31,179,621 (GBP) |
Funding ID | COV19 OxfordVacc-01 |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 03/2020 |
End | 03/2022 |
Description | nCoV: Rapid Clinical Development of ChAdOx1 nCoV-19 |
Amount | £2,174,847 (GBP) |
Funding ID | MC_PC_19055 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2020 |
End | 09/2021 |
Description | PHE |
Organisation | Public Health England |
Country | United Kingdom |
Sector | Public |
PI Contribution | Sharing protocols. |
Collaborator Contribution | Same. |
Impact | Ongoing. |
Start Year | 2019 |
Title | ChAdOx1 nCoV-19/AZD1222 |
Description | ChAdOx1 nCoV-19, initially supported by VaxHUb, has been in clinical trials in UK, SA, Brazil, Kenya, US, licensed in 60 countries for emergency use |
Type | Therapeutic Intervention - Vaccines |
Current Stage Of Development | Wide-scale adoption |
Year Development Stage Completed | 2020 |
Development Status | Under active development/distribution |
Clinical Trial? | Yes |
Impact | Demonstrated unprecedented speed of platform response. |
URL | https://www.isrctn.com/ISRCTN15281137?q=ChAdOx1%20nCoV-19&filters=&sort=&offset=5&totalResults=5&pag... |
Description | 18th International Congress of Immunology Cape Town South Africa - Keynote Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | 18th International Congress of Immunology Cape Town South Africa attendance Nov 27th- Dec 2nd 2023 and Keynote lecture on Development of Vaccines against Outbreak Pathogens enabling discussions with a wide variety of colleagues. |
Year(s) Of Engagement Activity | 2023 |
URL | https://iuis.org/events/iuis-2023/ |
Description | 2023 ISV Congress Chair - Next Generation Vaccines - 22-24 October 2023 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Chaired a Congress session at the 2023 International Society for Vaccines Annual meeting on Next Generation Vaccines, Lausanne Switzerland on 23rd October 2023. Participated in the congress 22-24 October 2023 engaging in discussions, with peers, industry professionals and students. |
Year(s) Of Engagement Activity | 2023 |
URL | https://isvcongress.org/node/217 |
Description | ATOM Festival Abingdon |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | Interactive science festival stand focused on how vaccines are made |
Year(s) Of Engagement Activity | 2022 |
Description | Adam Sweeting Lecture - University of Surrey- Preparing for Pandemic Vaccine Development - 18th May 2023 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | Participated in the Adam Sweeting Lecture series at the University of Surrey giving a talk on Preparing for Pandemic Vaccine Development on 18th May 2023. Answered questions afterwards and engaged in discussions of the topic with colleagues and other audience members. Attended a dinner with invited guests to continue discussions. |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.surrey.ac.uk/events/20230518-preparing-pandemic-vaccine-development |
Description | Advisory Board for World Innovation Summit for Health 2022 report on A new era for vaccine innovation - Doha Qatar |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Participation in the WISH event in Doha Qatar and active engagement as part of an Advisory group considering what we've learned thus far in order to prepare for future pandemic threats. A report was produced from discussions examining three main areas: the factors, enablers, and challenges of COVID-19 vaccine development; issues of access, equity and justice in vaccines and vaccination; and how lessons learned from COVID-19 vaccine development, production and deployment can be applied to other diseases. |
Year(s) Of Engagement Activity | 2022 |
URL | https://wish.org.qa/reports/a-new-era-for-vaccine-innovation/ |
Description | All-Party Parliamentary Group on Medical Research |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Policymakers/politicians |
Results and Impact | Aims of the event a) To bring Parliamentarians together with scientists and other life sciences sector representatives to recognise the exceptional efforts that have been made. b) To inform Parliamentarians of how decades of funding and support enabled the UK's broad and diverse medical research base to quickly pivot to tackle the pandemic. c) To highlight to Parliamentarians the importance of stable and sustainable long-term funding in a diversity of research fields, infrastructures, and research workforces to tackle current and future health challenges across the UK and internationally. |
Year(s) Of Engagement Activity | 2022 |
Description | Andrew Marr via BBC 7Feb2021 |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Impact unknown but reached a large audience. |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.bbc.co.uk/programmes/p09699wz |
Description | BBC Panorama Oxford COVID vaccine documentary |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | The inside story of the development of the Oxford vaccine against Covid-19. Fergus Walsh scrutinises the data that has come out of the trials, and examines the vaccination's efficacy and safety. |
Year(s) Of Engagement Activity | 2020 |
URL | https://www.bbc.co.uk/iplayer/episode/m000qdzd/panorama-the-race-for-a-vaccine |
Description | Cheltenham Science Festival Maker Shack |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | The Maker Shack at Cheltenham Science festival encourages interactive science engagement with a 'making theme'. Our 'Vaccine Maker' activity showcased how different vaccines including the Oxford Covid Vaccine were made. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.youtube.com/watch?v=GLGDG6tbUR4 |
Description | Cheney School Vaccine Hesitancy Workshop |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | A 2 hour interactive workshop testing new strategies for discussing vaccine hesitancy with secondary school pupils at the local Cheney School. |
Year(s) Of Engagement Activity | 2022 |
Description | Coalition for Global Prosperity Future Leaders Conference Speaker - The UK as a Health and Science 'Superpower' - 8th September 2023 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Coalition for Global Prosperity Future Leaders Conference Speaker - The UK as a Health and Science 'Superpower' - 8th September 2023 - Ditchley Park , UK - spoke about science as a collective endeavour and short-termism in the science community. Also held discussions with other invitees over coffee breaks and lunch on related topics. |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.coalitionforglobalprosperity.com/ditchley-park-retreat |
Description | Dhaka Literary Festival 2023, Bangladesh |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Participated in Women in Science section with Prof Hasina Khan and Prof Yasmeen Haque moderated by Dr Senjuti Saha and Science Vaxxers with Sadaf Saaz. |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.dhakalitfest.com/2023 |
Description | Doherty Institute Media Conference - Melbourne 27th September 2023 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | Discussion on COVID-19 - challenges, lessons learnt and where to next - in a media conference hosted by Melbourne Laureate Professor Sharon Lewin, Director of the Doherty Institute. |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.doherty.edu.au/news-events/news/covid-19-vaccines-with-special-guest-professor-dame-sara... |
Description | Elizabeth Blackwell Institute Annual Public Lecture - 6th October 2021 - hosted by University of Bristol |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Invited to give the Annual Elizabeth Public lecture on developing the Oxford AstraZeneca Covid-19 vaccine - held online hosted by the University of Bristol on 6th October 2021 |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.bristol.ac.uk/alumni/events/2021/elizabeth-blackwell-institute-lecture.html |
Description | Franco-British Young Leaders Seminar |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Policymakers/politicians |
Results and Impact | The Oxford Covid Vaccine team hosted the Franco-British Young Leaders for a seminar and tour of the Oxford labs. |
Year(s) Of Engagement Activity | 2022 |
URL | https://francobritish.org/en/young-leaders/ |
Description | History of Science Museum - Vaccines study days |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | A series of now bi-yearly events in collaboration with the History of Science Museum including talks on the the development of the Oxford Covid Vaccine, Vaccine Hesitancy workshops and meet the researcher opportunities for local GCSE and A Level students. |
Year(s) Of Engagement Activity | 2022 |
Description | Infection Prevention Society- 15th Annual Conference - Preparing for Pandemic Vaccine Development Talk - 19th October 2023 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Talk at the Infection Prevention Society Conference in Liverpool on 19th October 2023 followed by discussions with professionals, industrialists and other colleagues. |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.ips.uk.net/education-and-events |
Description | Invited Speaker to Master Course in Vaccinology and Drug Development- Siena, Italy - 6th-8th June 2023 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Talk on Outbreak Pathogens at the Pandemic Sciences Institute and Oxford Vaccine group in collaboration with Prof. Teresa Lambe at the Master Course in Vaccinology and Drug Development- Siena, Italy - 6th-8th June 2023. |
Year(s) Of Engagement Activity | 2023 |
Description | Keynote Panel Member - World Vaccine Congress- Barcelona October 17th 2023 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Participation in Keynote Panel: Getting ahead of the curve on pandemic preparedness discussing: -The evolution of COVID and the consequent role of current and next generation vaccines -How can we shorten/lower the epidemic curve rather than responding to and maintaining population immunity? -How can we most efficiently extrapolate the lessons from COVID to other priority pathogens of pandemic potential? -Where are the remaining vulnerabilities in the system and how can we better mitigate these for better pandemic preparedness? Moderated by Prof Isabel Oliver, Chief Scientific Advisor Transition Lead, UK Health Security Agency. with participation by EC, Moderna and CEPI Additionally participated in a vaccine safety discussion on ViTT, myocarditis & pericarditis: what are the next steps? 16th October 2023 and engaged with other Congress participants in attendance. |
Year(s) Of Engagement Activity | 2023 |
Description | Oxford University Alumni Network Victoria Dinner Presentation -Melbourne - 22nd September 2023 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Supporters |
Results and Impact | Reception and dinner talk given on vaccine development and chatted with members of the public and supporters participating in discussions and answering questions. |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.ousv.org/event-5368753 |
Description | Participation in Southeast Asia initiative to combat SARS-CoV-2 variants (SEACOVARIANTS) Meeting, Bangkok, Thailand, 28th - 29th January 2024 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Study participants or study members |
Results and Impact | Discussion of plans for the multidisciplinary research platform - Southeast Asia initiative to combat SARS-CoV-2 variants (SEACOVARIANTS), 2022-2025 in Bangkok, Thailand, 28th - 29th January 2024 |
Year(s) Of Engagement Activity | 2024 |
URL | https://www.oucru.org/project/seacovariants/ |
Description | Scaling Up Scotland Conference 3rd November 2023 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Industry/Business |
Results and Impact | Scaling up Scotland Conference and Networking Event 3rd November 2023. Talk on development of the ChAdOx1 Covid-19 vaccine and networking with entrepreneurs. |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.thehunterfoundation.co.uk/scaling-up-scotland-major-conference-and-networking-event-laun... |
Description | Supporting Women in MDHS (SWiM) Inspiring Stories Covid-19 Vaccine Development 27th September Doherty Institute |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | Telling the story of developing a new vaccine from scratch-in less than a year-including the logistical, regulatory, and technical issues involved. Prior to COVID-19, my team designed vaccines against Ebola, Mers and influenza, and used the same vaccine platform technology to create our COVID-19 vaccine. The conversation also covered early career interests and motivations, the development of the vaccine during the pandemic, the field of vaccine research since COVID-19, and how we prepare for the challenges ahead. |
Year(s) Of Engagement Activity | 2023 |
URL | https://paedacademy.medicine.unimelb.edu.au/events/3505 |
Description | Talk and Panel Discussion at International Society for Influenza and other Respiratory Virus Diseases- Seattle USA 1-3 March 2023 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Panel discussion on How can correlates of protection help the regulatory process for Licensure of New Vaccines. Talk on Lessons learned from new COVID vaccines at the International Society for Influenza and other Respiratory Virus Diseases held Seattle USA 1-3 March 2023 followed by discussions with colleagues, funding organisations and other participants. |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.isirv.org/site/images/conferences/Correlates_Seattle/Final%20Programme%2016%20February%2... |
Description | UK Pandemic Sciences Network Meeting- 5th-6th September 2023 Liverpool- Panel Member Science Communication in a Pandemic |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Participation in the UK Pandemic Sciences Network Meeting - From Regional, to National, To Global Resilience, 5th-6th September 2023, The Spine- Liverpool including a panel on Science Communication in a Pandemic with Fergus Walsh of the BBC and discussions with relevant pandemic preparedness scientists, media and officials. |
Year(s) Of Engagement Activity | 2023 |
URL | https://news.liverpool.ac.uk/2023/09/08/liverpool-welcomes-uks-top-pandemic-scientists/ |
Description | Vaccines Bioprocess Development and Commercialisation Workshop -13-15 June 2023- MIT, Cambridge MA, USA |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Gave a talk on the development of the Oxford AstraZeneca Covid-19 vaccine and participated in an expert panel on Accessibility and Platformability at the Vaccines Bioprocess Development and Commercialisation Workshop -13-15 June 2023 hosted by MIT in Cambridge MA, USA. Also participated in discussions with industrialists, funders and other scientific colleagues. |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.masslifesciences.com/event/vaccines-bioprocess-development-commercialization-workshop/ |
Description | Wychwood School Medical Chemistry Conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | Support for the local school conference with recorded Keynote introduction from Prof Sarah Gilbert. Promoting the idea that vaccine development and manufacture is a multidisciplinary subject. |
Year(s) Of Engagement Activity | 2022 |
Description | Wycliffe College: Primary School STEM Day |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | STEM focused interactive activity day for primary school aged children. The event was hosted by a high school with students taking the role as science facilitators, supported by scientists. Theme was vaccine research. |
Year(s) Of Engagement Activity | 2022 |
Description | mRNA 3rd Scientific Colloquium on vaccine access and equity on the African continent - Keynote address Assessing Impact of access to mRNA vaccines in LMICs |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Third sector organisations |
Results and Impact | mRNA 3rd Scientific Colloquium on vaccine access and equity on the African continent meeting hosted by Afrigen Biologics 27th November 2023 - Keynote address Assessing Impact of access to mRNA vaccines in LMICs. Followed by questions and discussions with participating scientists, policy makers and industrialists. |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.afrigen.co.za/2023/11/29/mmrna-scientific-colloquium-on-vaccine-access-and-equity-on-the... |